News & Resources

New Day Diagnostics LLC Reinforces Commitment to Early Cancer Intervention with its Intention to Acquire the Assets of Epigenomics AG

New Day Diagnostics LLC is set to revolutionize cancer diagnostics through a strategic asset purchase agreement with Epigenomics AG. This move enhances their mission to provide cost-effective early detection products, with a focus on Epi proColon, a groundbreaking colorectal cancer screening tool. CEO Eric Mayer sees vast potential in the methylated DNA biomarker, and the acquisition aims to accelerate its commercialization. Jens Ravens of Epigenomics expressed confidence in the synergy between the companies, highlighting the promise of accessible blood-based cancer diagnostics. New Day Diagnostics remains dedicated to making healthcare more accessible and convenient, using the Epigenomics assets to further innovate in the diagnostic testing space.